- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04647682
Physical Activity Program Implementation in Hospitalized Positive COVID-19 Older Adults (Cov-activity)
Feasibility and Effect of Implementing Physical Activity Program Implementation During COVID-19 in Hospitalized Positive COVID-19 Older Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The 30 second chair test, balance with joint-feet and semi-tandem stance, and 4 meters comfortable walking test were evaluated. Depending on their score, a specific physical activity (PA) program was selected and explained. The program was printed, explained and left in the room. This intervention included 5 different PA programs.
Final evaluation (one day before leaving the unit) recording physical performance (same physical tests used for inclusion evaluation), Hospital Anxiety and depression (HAD) score, Activities Daily Living (ADL) and self-satisfaction of the program.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Grenoble, France
- CHU de Grenoble
-
Toulouse, France, 31059
- University Hospital Toulouse
-
-
-
-
-
Pointe-à-Pitre, Guadeloupe
- CHU Pointe-à-Pitre Abîmes - GUADELOUPE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged 75 years and over
- Hospitalized in a French COVID-19 geriatric unit
- Positive COVID-19 infection made by Real-time Polymerase Chain Reaction COVID-19 or suspected on thoracic lesions on computerized tomography.
Exclusion Criteria:
- Exclusion of patients of palliative care,
- Severe dementia or Mini Mental State Examination (MMSE) [14] below 18/30
- Acute COVID-19 complication.
- Activities of Daily Living < 2/6
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
One single group study
Patients aged 75 years and over Hospitalized in a French COVID-19 geriatric unit Positive COVID-19 infection made by Real-time Polymerase Chain Reaction COVID-19 or suspected on thoracic lesions on computerized tomography.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of adherence of the intervention
Time Frame: through study completion, an average of 15 days
|
adherence of the intervention evaluated by the number of completed exercise days compared to the number of total intervention days
|
through study completion, an average of 15 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of physical performances
Time Frame: through study completion, an average of 15 days
|
Comparison between inclusion and final physical performances measured by the 30-second chair test, balance with joint-feet, semi-tandem stance, 4 meters comfortable walking test, functional abilities with the evaluation of ADL score and HAD scores.
|
through study completion, an average of 15 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yves Rolland, MD, University Hospital, Toulouse
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/20/0145
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Infection
-
PfizerActive, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionUnited States
-
PfizerRecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionBelgium
-
Aga Khan UniversityCompletedCOVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Lower Respiratory InfectionPakistan
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCOVID-19 | Coronavirus Disease 2019 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome | COVID-19 Acute Bronchitis | COVID-19 Lower Respiratory InfectionUnited States
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruitingCOVID-19 Vaccine | COVID-19 Respiratory Infection | SARS CoV 2 InfectionUnited States
-
Catalysis SLCompletedRespiratory Tract Infections | Covid19 | SARS-CoV2 Infection | COVID-19 Pneumonia | COVID-19 Respiratory Infection | Viral Infection | Infection, CoronavirusKazakhstan
-
KARE BiosciencesBiomedical Advanced Research and Development Authority; BioLink Life Sciences... and other collaboratorsRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory InfectionIndia
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... and other collaboratorsCompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV DiseaseUnited States
-
bioLytical LaboratoriesCompletedCOVID-19 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19United States
-
Tiziana Life Sciences LTDWithdrawnCovid19 | COVID-19 Respiratory Infection | COVID-19 Lower Respiratory Infection
Clinical Trials on physical activity program
-
Universidad Santo TomasEmory University; Universidad Pública de Navarra; Universidad de Granada; University... and other collaboratorsCompletedObesity | Lipid Metabolism Disorders | Mental Health Wellness 1 | Body Composition, Beneficial | Metabolic Syndrome X
-
University Hospital, Clermont-FerrandRecruiting
-
Case Western Reserve UniversityNational Multiple Sclerosis SocietyCompletedMultiple SclerosisUnited States
-
Assistance Publique Hopitaux De MarseilleRecruiting
-
University of Illinois at Urbana-ChampaignUniversity of ArizonaCompleted
-
Fundacion para la Investigacion y Formacion en...CompletedImpaired CognitionSpain
-
Centre Hospitalier Universitaire de NiceNot yet recruiting
-
ElsanNot yet recruitingIndividualised Physical Activity Program | Coronary Patient
-
University Hospital of FerraraUniversità degli Studi di FerraraCompletedChronic Kidney Disease Stage 5 on DialysisItaly
-
Centre Hospitalier Universitaire de Saint EtienneJean Monnet UniversityRecruiting